![]() Seven patients (22%) received Idarucizumab before intravenous thrombolysis due to ischemic stroke and 4 of these 7 patients (13%) received mechanical thrombectomy in addition. Nine patients (28%) underwent emergency surgery. Additional coagulation management was performed in 7 patients (22%). Idarucizumab was administered to 32 patients for severe bleeding complications and ischemic strokes, more precisely for the following specific indications: intracranial bleeding (17 patients, 53%), ischemic stroke (8 patients, 25%), gastrointestinal bleeding (3 patients, 9%), femoral fracture, aortic dissection, and abdominal trauma and ileus (1 patient each, 3%). Indication and application of Idarucizumab, demographics and clinical parameters, and further interventions and treatments clinical outcome was assessed with the modified Rankin scale (mRS) at 3 months after Idarucizumab administration Results SettingĪll hospitals with full neurological departments ( n = 6) in Munich, Germany Included patientsĪll patients treated with Idarucizumab from 01/2016 to 03/2019. Multicenter observational registry study. To evaluate daily life management and functional outcome of Idarucizumab administration in case of emergency situations in patients with Dabigatran treatment.
0 Comments
Leave a Reply. |